We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations

    Guilherme Suarez-Kurtz

    *Author for correspondence: Tel.: +55 213 207 6552;

    E-mail Address: kurtz@inca.gov.br

    Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional de Câncer, Rio de Janeiro, Brazil

    Search for more papers by this author

    &
    Claudio José Struchiner

    Escola de Matemática Aplicada, Fundação Getúlio Vargas, Rio de Janeiro, RJ, Brazil

    Search for more papers by this author

    Published Online:20 Mar 2024https://doi.org/10.2217/pgs-2024-0009

    Abstract

    This study shows that the distribution of CYP3A5 alleles (*1, *3, *6 and *7) and genotype-predicted CYP3A5 phenotypes vary significantly across Latin American cohorts (Brazilians and the One Thousand Genomes Admixed American superpopulation), as well as among subcohorts comprising individuals with the highest proportions of Native, European or sub-Saharan African ancestry. Differences in biogeographical ancestry across the study groups are the likely explanation for these results. The differential distribution of CYP3A5 phenotypes has major pharmacogenomic implications, affecting the proportion of individuals carrying high risk CYP3A5 phenotypes for the immunosuppressant tacrolimus and the number of patients that would need to be genotyped to prevent acute rejection in kidney transplant recipients under tacrolimus treatment.

    References

    • 1. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271–1294 (2002).
      Medline CASGoogle Scholar
    • 2. Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics Genom. 22(7), 555–558 (2012).
      Medline CASGoogle Scholar
    • 3. Birdwell KA, Decker B, Barbarino JM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther. 98(1), 19–24 (2015).
      Medline CASGoogle Scholar
    • 4. Pratt VM, Cavallari LH, Fulmer ML et al. CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J. Mol. Diagn. 25(9), 619–629 (2023).
      Medline CASGoogle Scholar
    • 5. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383–391 (2001).
      Medline CASGoogle Scholar
    • 6. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773–779 (2001).
      Medline CASGoogle Scholar
    • 7. Auton A, Brooks LD, Durbin RM et al. 1000 Genomes Project Consortium; a global reference for human genetic variation. Nature 526(7571), 68–74 (2015).
      MedlineGoogle Scholar
    • 8. Suarez-Kurtz G, Vargens DD, Santoro AB et al. Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population. PLOS ONE 9(1), e83472 (2014).
      MedlineGoogle Scholar
    • 9. Debortoli G, de Araujo GS, Fortes-Lima C, Parra EJ, Suarez-Kurtz G. Identification of ancestry proportions in admixed groups across the Americas using clinical pharmacogenomic SNP panels. Sci. Rep. 11(1), 1007 (2021).
      Medline CASGoogle Scholar
    • 10. Pena SD, Di Pietro G, Fuchshuber-Moraes M et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLOS ONE 6(2), e17063 (2011).
      Medline CASGoogle Scholar
    • 11. Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer NY, USA (2002).
      Google Scholar
    • 12. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing Vienna, Austria (2023).
      Google Scholar
    • 13. Tonk ECM, Gurwitz D, Maitland-van der Zee AH, Janssens ACJW. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 17(4), 386–392 (2017).
      Medline CASGoogle Scholar
    • 14. Rojas L, Neumann I, Herrero MJ et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 15(1), 38–48 (2015).
      Medline CASGoogle Scholar
    • 15. Cohen J. Statistical Power Analysis for the Behavioral Sciences (Second Edition). Lawrence Erlbaum Associates Publishers NJ, USA (1988).
      Google Scholar
    • 16. Wright S. Variability within and among Natural Populations. University of Chicago Press, IL, USA (1978).
      Google Scholar
    • 17. Bonifaz-Peña V, Contreras AV, Struchiner CJ et al. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. PLOS ONE 9(11), e112640 (2014).
      MedlineGoogle Scholar
    • 18. Fohner AE, Dalton R, Skagen K et al. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function. Clin. Transl. Sci. 14(4), 1292–1302 (2021).
      Medline CASGoogle Scholar
    • 19. Santoro A, Felipe CR, Tedesco-Silva H et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 12(9), 1293–1303 (2011).
      CASGoogle Scholar
    • 20. Cusinato DA, Lacchini R, Romao EA, Moysés-Neto M, Coelho EB. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br. J. Clin. Pharmacol. 78(2), 364–372 (2014).
      Medline CASGoogle Scholar
    • 21. Everton JBF, Patrício FJB, Faria MS et al. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients. Eur. J. Clin. Pharmacol. 77(6), 879–886 (2021).
      Medline CASGoogle Scholar
    • 22. Contreras-Castillo S, Plaza A, Stojanova J et al. Effect of CYP3A4, CYP3A5, MDR1 and POR genetic polymorphisms in immunosuppressive treatment in Chilean kidney transplanted patients. Front. Pharmacol. 12, 674117 (2021).
      MedlineGoogle Scholar
    • 23. García-Roca P, Medeiros M, Reyes H et al. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch. Med. Res. 43(4), 283–287 (2012).
      Medline CASGoogle Scholar